NEJM病例:是谁,夺去了这位年轻女性的心跳?

2018-05-23 英硕 医学界心血管频道

“铃铃铃”,急诊室的电话突然响起,电话另一头传来一位女性急促的声音:“医生,快来救救我的女儿,她现在倒在地上,已经没有心跳了”。

早晨08:45

“铃铃铃”,急诊室的电话突然响起,电话另一头传来一位女性急促的声音:“医生,快来救救我的女儿,她现在倒在地上,已经没有心跳了”。

听到这句话,我(Joshua N. Goldstein)陷入了片刻沉思——死神降临在一位年轻女性的身上。医生的责任感打断了沉思,我立刻用沉稳地声音详细询问了患者的家庭住址,迅速组织同事奔赴事发地点。

早晨08:54

我们到达了现场,发现一位意识丧失的年轻女性躺在地上,另一位中年女性正在对其进行心肺复苏,患者身上已连接了一台简易的体外自动除颤仪。

经过简单询问证实躺着的就是患者,而实施抢救的是她的母亲。据这位母亲描述,在我们到达前,除颤仪已放电一次。

我们立即搀扶起患者母亲,继续对患者进行心肺复苏,同时给予气管插管,并建立静脉通路,输注碳酸氢钠、肾上腺素和氯化钙,患者逐渐恢复自主循环。随后我们迅速将患者搬运至救护车上,此时患者心跳再次停止,我们再次给予心肺复苏和肾上腺素。

早晨9:16

“咚—咚—咚”,患者心跳再次恢复,心电监护显示心率94次/分,血压66/30mmHg,呼吸7次/分,患者血压偏低,立即予生理盐水扩容,多巴胺升压。

早晨9:38

救护车到达急诊室门口,我们迅速将患者转运至监护室,仔细评估患者病情,并询问其母亲该患者发病前情况和既往史。

生命体征:体温35.9℃,脉搏97次/分,血压60/24mmHg,呼吸25次/分;

查体:患者反应迟钝,外周皮肤部分破溃,双侧瞳孔等大等圆(直径6mm),对光反射、角膜反射、呕吐反射(-),无自主呼吸。

心电图如下(图1),为宽QRS波心动过速。


图1 宽QRS波心动过速,QRS波宽220ms,V1导联R波向上,类似右束支图形,aVR导联R波向上,电轴右偏

其母亲回忆说:“我女儿昨晚喝醉了,在今晨07:45回到自己卧室,进卧室前精神状态没有异常,约1小时后我敲她房门,却没有应答,于是我开门后发现她已经倒在地上。”

“她以前有其他疾病吗?”我接着问。

“她有抑郁症,经常喝酒,甚至吸毒。”她母亲无奈地说。

生命转瞬即逝,在对患者进行复苏治疗的同时,我也在思考是谁“夺去了”这位年轻女性的心跳。我迅速向上级医师汇报了患者的情况,上级医师立即组织全科进行疑难危重病例讨论。

病例讨论

Dr.David M. Dudzinski:“根据患者心电图考虑宽QRS波心动过速,需要鉴别室速、室上速伴差异性传导和室上速伴旁路前传。引起QRS波增宽的常见疾病有心肌梗死、心肌病、电解质紊乱和药物中毒。该患者QRS波增宽、有右束支阻滞图形、aVR导联R波向上、电轴右偏,考虑室速。需明确室速原因。”

Dr. Cleveland:对患者给予常规实验室检查、毒物分析和器械检查。

我:该患者为年轻女性,既往有精神疾病,发病前60分钟内精神状态未见明显异常,缺乏导致患者心电图QRS波增宽的疾病,极有可能是药物所致,特别是钠通道阻滞剂,而三环类抗抑郁药可阻断钠通道。

在进行这些检查的同时,我们根据经验给予葡萄糖、镁、碳酸氢钠等治疗。实验室检查提示血钾、钠、镁、钙、肌钙蛋白未见异常;估测的肾小球滤过率提示中度肾功能不全;血气分析提示代谢性酸中毒;器械检查中超声心动图提示心脏结构功能正常。因此,可排除心肌梗死、心肌病、电解质紊乱导致室速。

此时,毒物分析结果支持我们的诊断——三环类抗抑郁药过量。

那该如何治疗呢?

针对三环类抗抑郁药,有以下治疗方案:

通畅气道、吸氧、静脉补液;

胃肠道清除,针对摄入抗抑郁药物1h以内者;

静脉输注碳酸氢钠;

纠正电解质紊乱等。

其中,碳酸氢钠在治疗三环类抗抑郁药治疗中具有不可替代的作用。作用机制有碱化血液、改变细胞极性、降低血药浓度、增加钠浓度、改善心肌钠通道稳定性。

经过这些治疗后,患者除精神状态、生命体征逐渐恢复正常,心电图有明显变化(图2、图3)。10天后患者好转出院。


图2 治疗3h后QRS波宽度为140ms,aVR导联主波向下,P波可见


图3 治疗24h后QRS波宽度为110ms,心率84次/分

原始出处:

1. Goldstein JN, Dudzinski DM, Erickson TB,et al. Case 12-2018: A 30-Year-Old Woman with Cardiac Arrest.N Engl J Med.  2018Apr 19;378(16):1538-1549.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=319260, encodeId=114b319260d9, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 28 07:18:35 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514984, encodeId=75831514984c8, content=<a href='/topic/show?id=b593489e75b' target=_blank style='color:#2F92EE;'>#年轻女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48977, encryptionId=b593489e75b, topicName=年轻女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b410702302, createdName=thinkibmz_44722597, createdTime=Fri May 25 12:55:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318077, encodeId=ecd43180e70c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 24 07:29:07 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317986, encodeId=33c931e98669, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:37 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317985, encodeId=1c0131e9853c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:05 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317924, encodeId=b6fe31e92461, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e462362503, createdName=122d508am87暂无昵称, createdTime=Wed May 23 22:26:33 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-28 张新亮1853311252142e2fm

    好文献学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=319260, encodeId=114b319260d9, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 28 07:18:35 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514984, encodeId=75831514984c8, content=<a href='/topic/show?id=b593489e75b' target=_blank style='color:#2F92EE;'>#年轻女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48977, encryptionId=b593489e75b, topicName=年轻女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b410702302, createdName=thinkibmz_44722597, createdTime=Fri May 25 12:55:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318077, encodeId=ecd43180e70c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 24 07:29:07 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317986, encodeId=33c931e98669, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:37 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317985, encodeId=1c0131e9853c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:05 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317924, encodeId=b6fe31e92461, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e462362503, createdName=122d508am87暂无昵称, createdTime=Wed May 23 22:26:33 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=319260, encodeId=114b319260d9, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 28 07:18:35 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514984, encodeId=75831514984c8, content=<a href='/topic/show?id=b593489e75b' target=_blank style='color:#2F92EE;'>#年轻女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48977, encryptionId=b593489e75b, topicName=年轻女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b410702302, createdName=thinkibmz_44722597, createdTime=Fri May 25 12:55:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318077, encodeId=ecd43180e70c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 24 07:29:07 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317986, encodeId=33c931e98669, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:37 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317985, encodeId=1c0131e9853c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:05 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317924, encodeId=b6fe31e92461, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e462362503, createdName=122d508am87暂无昵称, createdTime=Wed May 23 22:26:33 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-24 张新亮1853311252142e2fm

    好文献学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=319260, encodeId=114b319260d9, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 28 07:18:35 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514984, encodeId=75831514984c8, content=<a href='/topic/show?id=b593489e75b' target=_blank style='color:#2F92EE;'>#年轻女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48977, encryptionId=b593489e75b, topicName=年轻女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b410702302, createdName=thinkibmz_44722597, createdTime=Fri May 25 12:55:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318077, encodeId=ecd43180e70c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 24 07:29:07 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317986, encodeId=33c931e98669, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:37 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317985, encodeId=1c0131e9853c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:05 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317924, encodeId=b6fe31e92461, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e462362503, createdName=122d508am87暂无昵称, createdTime=Wed May 23 22:26:33 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-24 724765917_36481625

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=319260, encodeId=114b319260d9, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 28 07:18:35 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514984, encodeId=75831514984c8, content=<a href='/topic/show?id=b593489e75b' target=_blank style='color:#2F92EE;'>#年轻女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48977, encryptionId=b593489e75b, topicName=年轻女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b410702302, createdName=thinkibmz_44722597, createdTime=Fri May 25 12:55:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318077, encodeId=ecd43180e70c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 24 07:29:07 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317986, encodeId=33c931e98669, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:37 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317985, encodeId=1c0131e9853c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:05 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317924, encodeId=b6fe31e92461, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e462362503, createdName=122d508am87暂无昵称, createdTime=Wed May 23 22:26:33 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-24 724765917_36481625

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=319260, encodeId=114b319260d9, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 28 07:18:35 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514984, encodeId=75831514984c8, content=<a href='/topic/show?id=b593489e75b' target=_blank style='color:#2F92EE;'>#年轻女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48977, encryptionId=b593489e75b, topicName=年轻女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b410702302, createdName=thinkibmz_44722597, createdTime=Fri May 25 12:55:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318077, encodeId=ecd43180e70c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 24 07:29:07 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317986, encodeId=33c931e98669, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:37 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317985, encodeId=1c0131e9853c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/13/e51eda1902bf3197b7b2a48e1ba1e39c.jpg, createdBy=6a672335244, createdName=724765917_36481625, createdTime=Thu May 24 00:36:05 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317924, encodeId=b6fe31e92461, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e462362503, createdName=122d508am87暂无昵称, createdTime=Wed May 23 22:26:33 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-23 122d508am87暂无昵称

    学习了

    0

相关资讯

Plos Biol:科学家研究发现:为什么抗抑郁药在某些人身上没有效果!

治疗抑郁症的主要障碍之一就是抗抑郁剂是有效的选择,但它们在所有患者中不作用。他们不适合所有患有这种疾病的人。 科学家报告了一个可能解释为什么是这样的发现。

Ann Oncol:肿瘤医生对患者使用抗抑郁药的几点建议

2018年1月,发表在《Ann Oncol》的一项由意大利和加拿大科学家进行的分析,考察了肿瘤患者使用抗抑郁药的有效性和安全性,并对肿瘤医生在临床中的实践提出一些建议。

BMC Med.:考察妊娠期抗抑郁药与ASD和ADHD风险相关性的观察性研究有何局限?

2018年1月,发表在《BMC Med》的一项由英国科学家进行的观察性研究的系统评价,强调了评估妊娠期使用抗抑郁药与自闭症谱系障碍(ASD)和注意缺陷多动障碍(ADHD)的风险之间的相关性的观察性研究的方法学局限性。

别让误解“玩坏”了抗抑郁药

临床上药物种类繁多,每一类药物都有其特殊性,抗抑郁药更是如此。然而,部分患者由于对抗抑郁药物的认识不到位,导致药物不起效,甚至被乱用、弃用,本文章将介绍临床上部分患者对抗抑郁药常见的误解及正确认识。

Lancet:一项研究指抗抑郁药有效:“平息了医学界一大争议”

据外媒报道,抗抑郁药究竟有没有效?研究者说,一项最新研究的结果,平息了医学界其中一个最大的争议

支持抗抑郁药的疗效的主要研究

一项针对最常见的抗抑郁药的大型综述发现,在治疗重度抑郁症时,它们都优于安慰剂,这可能会让人们对其有效性提出质疑。研究人员对21种用于严重抑郁症成人急性治疗的抗抑郁药的安慰剂对照和头对头试验的数据进行了系统评价和网络荟萃分析。发表在《柳叶刀》上的数据显示,研究中包含的所有抗抑郁药都比安慰剂更有效,但也突出了药物之间的关键区别。首先,优势比(衡量暴露与结局之间的关联)介于阿替西平2.13至瑞波西汀1.